PART1 promotes resistance by competitively binding to miR‐129 to increase Bcl‐2 expression and knockdown of PART1 effectively improves gefitinib sensitivity in ESCC cells.[121] Zhang et al. The gene discussed is PART1; the disease is esophageal squamous cell carcinoma.